Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

FBIOP - Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A


Previous close
6.65
0   0%

Share volume: 5,078
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$6.65
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.92%
1 Month
-26.74%
3 Months
-57.36%
6 Months
-53.50%
1 Year
-22.66%
2 Year
-47.34%
Key data
Stock price
$6.65
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$6.10 - $17.26
52 WEEK CHANGE
-$0.23
MARKET CAP 
46.312 M
YIELD 
26.69%
SHARES OUTSTANDING 
3.427 M
DIVIDEND
$0.1953
EX-DIVIDEND DATE
06/14/2024
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$15,555
AVERAGE 30 VOLUME 
$26,359
Company detail
CEO: Lindsay Rosenwald
Region: US
Website: http://www.fortressbiotech.com
Employees: 38
IPO year: -
Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

fortress biotech, inc. is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as fortress companies. the company will leverage its biopharmaceutical business expertise and drug development capabilities to help the fortress companies achieve their goals. additionally, the company will provide funding and management services to each of the fortress companies and from time to time the company and the fortress companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.

Recent news